

PRESS RELEASE

Aquilab joins the Coexya group

The acquisition will enable Coexya to strengthen its leadership position in healthcare and more specifically in oncology.

Lyon (France), April 21st 2022 – Coexya, an independent digital leader in consulting, integration and software development, is to acquire Aquilab, a software company specialised in healthcare. The transaction will be a strategic merger of the two companies, enabling them to pursue their development.

Based in northern France, Aquilab has been a recognised software provider in the field of oncology for more than 20 years. Aquilab's range of software and services improves the quality of treatment:

- ▶ **ARTISCAN** ensures the quality of imaging and radiotherapy equipment.
- ▶ **ARTIVIEW** improves the preparation and evaluation of radiotherapy treatment.
- ▶ **ONCO PLACE**, evaluates and identifies new therapeutic strategies for its more than 4,000 users through the analysis of its clinical study database.

Both companies are strong in healthcare and oncology data. The merger will take advantage of their complementary nature and enable them to create multi-centric clinical studies. Coexya will use its **ConSore** solution to create cohorts of patients, while Aquilab will use **ONCO PLACE** to manage clinical studies. Coexya will be able to share its expertise with Aquilab's 350 European customers, and Aquilab will be able to accelerate its product development thanks to Coexya's recognised expertise in data processing and artificial intelligence.

Healthcare accounts for 15% of Coexya's activities. The company provides the sector with its **OdyCare by Coexya** software and its integration services. Coexya understands the challenges its customers face and supports them in their digital transition. Their appropriate, ergonomic solutions make it easier to offer coordinated care, to guide patients and get more value from its patient data.

Philippe le Calvé, CEO of Coexya, said, "I am particularly pleased that Coexya is acquiring Aquilab, a company active in the healthcare sector. Our customers will be able to take advantage of an expanded range of services in France and abroad. We are delighted to welcome Aquilab's employees into our group through a transaction that will also enable us to develop in the region of Lille.

David Gibon, Aquilab's chief executive, said, "For more than 20 years, we have been providing innovative products devoted to improving the quality of cancer treatment. The merger with Coexya will enable us to strengthen our expertise in data and AI so as to step up our development in predictive medicine. Aquilab and Coexya have customers in common and share the same values. By leveraging these synergies, we will be able to propose new solutions and provide better treatment to people suffering from cancer."

About Coexya

Coexya has more than 20 years of experience in consulting, integration and software development and is specialised in digital transformation. In 2020, Coexya changed shareholders and with the support of

its executives, operational managers and the European investment fund Argos Wityu, became independent of the Sword Group. Coexya's mission is to support organisations by developing solutions that address the new ways employees and customers use data. Coexya is active in six areas of expertise: customer experience, digital content, health, legal, location intelligence and smart data.

The group serves more than 370 clients and generated turnover of nearly €70m in 2021. Coexya has more than 700 employees based in Lille, Brest, Lyon, Paris and Rennes.

More information on www.coexya.eu

About Aquilab

Aquilab is a French SME which develops advanced solutions for quality assurance of medical imaging and radiotherapy equipment (CT, MRI, Nuclear Medicine, Radiology...) and for quality improvement in radiotherapy treatment.

More than 350 clinics in France and outside use Aquilab products, including the most advanced radiotherapy centers in France. Aquilab has become a benchmark in the market of quality assurance for medical imaging and is rapidly growing in the preparation and evaluation of radiotherapy treatment market. Its Onco Place platform is currently used by more than 4000 users in 60 countries.

More information on www.aquilab.com

Press contact

Carine Groz

Communication Manager

carine.groz@coexya.eu

+33 6 14 01 15 58